Amikacin Liposome Inhalation Suspension Clinical Benefit-Risk Assessment for Refractory MAC Lung Disease

[1]  S. Field,et al.  Amikacin Liposome Inhalation Suspension for Refractory MAC Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-Term Exposure. , 2021, Chest.

[2]  J. Yim,et al.  Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial , 2020, Annals of the American Thoracic Society.

[3]  J. Brożek,et al.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline , 2020, European Respiratory Journal.

[4]  R. Diel,et al.  High mortality in patients with Mycobacterium avium complex lung disease: a systematic review , 2018, BMC Infectious Diseases.

[5]  J. Yim,et al.  Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Addrizzo-Harris,et al.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease , 2016, American journal of respiratory and critical care medicine.

[7]  T. Ketter,et al.  When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed , 2013, International journal of clinical practice.

[8]  N. Ampel.  Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .

[9]  J. Caro,et al.  Comparing medications in a therapeutic area using an NNT model. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  K. Winthrop,et al.  Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT) , 2018 .